Immune checkpoint inhibitor therapy in COPD-concomitant lung cancer: A review of efficacy outcomes and mechanistic insights
Cancer Letters · 2026-12 · 663 · 218933
DOI: 10.1016/j.canlet.2026.218933 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Letters, 2026-12. Verfasst von Yingjiao Long und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China; Research U…. Die Arbeit nennt 134 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Hunan Provincial Natural Science Foundation.
Themen: COPD
Abstract (Originalsprache)
The coexistence of chronic obstructive pulmonary disease (COPD) and lung cancer (LC) presents a complex clinical scenario with distinct pathological interactions. Beyond shared epidemiological and genetic risk factors, COPD reshapes the pulmonary immune microenvironment through reprogrammed immune-cell compartments, aberrant programmed cell death, and epithelial-mesenchymal transition (EMT), fostering an immunologically "hot" but pathologically permissive milieu that simultaneously drives carcinogenesis and influences treatment responsiveness. Recent evidence suggests that COPD may confer an altered immunological microenvironment that paradoxically enhances responsiveness to immune checkpoint inhibitors (ICIs) in patients with LC. This review mainly synthesizes clinical evidence on the efficacy of ICI, currently the most widely used immunotherapy, in LC patients concomitant with COPD and elucidates potential immunological and molecular mechanisms underlying observed clinical benefits, including heightened programmed cell death protein ligand 1 (PD-L1) expression, elevated tumor mutational burden, increased human leukocyte antigen I (HLA-I) expression, enriched tissue-resident memory T cells and mucosal-associated invariant T cells, and a macrophage polarization shift toward a pro-inflammatory phenotype, with benefits appearing largely attributable to patients with mild-to-moderate airflow obstruction. The safety profile of ICIs in this population-exacerbation risk, eosinophilic airway disease, checkpoint inhibitor pneumonitis (CIP), and autoimmune thyroiditis-is appraised, alongside emerging strategies such as lymphocyte-activation gene 3 (LAG-3), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), and T cell immunoreceptor with Ig and ITIM domains (TIGIT) blockade and the immunomodulatory potential of COPD medications (inhaled corticosteroids and long-acting β-agonists). Current evidence remains limited by small retrospective cohorts and heterogeneous stratification. Large-scale prospective studies are warranted. This review aims to clarify the prognostic value of concomitant COPD and guide precision therapeutic strategies for this growing comorbid population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China; Research Unit of Respiratory Disease, Central South University, Changsha, Hunan,…
- Department of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
- Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, NHC Key Laboratory of Carcinogenesis, Cancer Research Institute, School of Basic Medical Sciences, Central South University, Changsha, Hunan…
- Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China; Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, NHC Key Laboratory…
Förderung
- National Natural Science Foundation of China
- Hunan Provincial Natural Science Foundation
Zitieren
APA
Long, Y., Liu, Y., Miao, K., Xiao, D., Chen, Y., Chen, L., & Tao, Y. (2026). Immune checkpoint inhibitor therapy in COPD-concomitant lung cancer: A review of efficacy outcomes and mechanistic insights. Cancer Letters, 663, 218933. https://doi.org/10.1016/j.canlet.2026.218933
Vancouver
Long Y, Liu Y, Miao K, Xiao D, Chen Y, Chen L, et al. Immune checkpoint inhibitor therapy in COPD-concomitant lung cancer: A review of efficacy outcomes and mechanistic insights. Cancer Letters. 2026;663:218933. doi:10.1016/j.canlet.2026.218933
BibTeX
@article{Long2026,
author = {Long, Yingjiao and Liu, Yidian and Miao, Kangping and Xiao, Desheng and Chen, Yan and Chen, Ling and Tao, Yongguang},
title = {Immune checkpoint inhibitor therapy in COPD-concomitant lung cancer: A review of efficacy outcomes and mechanistic insights},
journal = {Cancer Letters},
year = {2026},
volume = {663},
pages = {218933},
doi = {10.1016/j.canlet.2026.218933}
}
EUVIMED